Treatment of oral cancer using magnetized paclitaxel

Rina Nakakaji; Masanari Umemura; Kenji Mitsudo; Jeong-Hwan Kim; Yujiro Hoshino; Itaru Sato; Takatsugu Masuda; Masahiro Yamamoto; Mitomu Kioi; Toshiyuki Koizumi; Takayuki Fujita; Utako Yokoyama; Masaki Iida; Motohiko Sato; Hiroshi Sato; Shoko Murofushi; Sayaka Shibata; Ichio Aoki; Haruki Eguchi; Iwai Tohnai; Yoshihiro Ishikawa

doi:10.18632/oncotarget.24570

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Treatment of oral cancer using magnetized paclitaxel

Rina Nakakaji, Masanari Umemura _, Kenji Mitsudo, Jeong-Hwan Kim, Yujiro Hoshino, Itaru Sato, Takatsugu Masuda, Masahiro Yamamoto, Mitomu Kioi, Toshiyuki Koizumi, Takayuki Fujita, Utako Yokoyama, Masaki Iida, Motohiko Sato, Hiroshi Sato, Shoko Murofushi, Sayaka Shibata, Ichio Aoki, Haruki Eguchi, Iwai Tohnai and Yoshihiro Ishikawa

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2018; 9:15591-15605. https://doi.org/10.18632/oncotarget.24570

Metrics: PDF 1416 views | HTML 3799 views | ?

Abstract

Rina Nakakaji1,2,*, Masanari Umemura1,*, Kenji Mitsudo2, Jeong-Hwan Kim1, Yujiro Hoshino3, Itaru Sato1,2, Takatsugu Masuda4, Masahiro Yamamoto5, Mitomu Kioi2, Toshiyuki Koizumi2, Takayuki Fujita1, Utako Yokoyama1, Masaki Iida2, Motohiko Sato6, Hiroshi Sato7, Shoko Murofushi7, Sayaka Shibata8, Ichio Aoki8, Haruki Eguchi7, Iwai Tohnai2 and Yoshihiro Ishikawa1

1Cardiovascular Research Institute, Yokohama City University Graduate School of Medicine, Yokohama, Japan

2Department of Oral and Maxillofacial Surgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan

3Department of Environment and Natural Sciences, Yokohama National University Graduate School of Environment and Information Sciences, Yokohama, Japan

4Tokyo Neutron Science Laboratory, Tokyo University Institute for Solid State Physics, Kashiwa, Japan

5Department of Chemistry of Functional Molecules, Konan University Faculty of Science and Engineering, Kobe, Japan

6Department of Physiology, Aichi Medical University, Nagakute, Japan

7Advanced Applied Science Department, Research Laboratory, IHI Corporation, Yokohama, Japan

8Molecular Imaging Center, National Institute of Radiological Sciences, Chiba, Japan

*These authors contributed equally to this work

Correspondence to:

Masanari Umemura, email: [email protected]

Yoshihiro Ishikawa, email: [email protected]

Keywords: iron-salen; taxol; oral cancer; paclitaxel; magnetism

Received: July 14, 2017 Accepted: February 20, 2018 Epub: February 26, 2018 Published: March 20, 2018

ABSTRACT

N,N’-Bis(salicylidene)ethylenediamine iron (Fe(Salen)) is an anti-cancer agent with intrinsic magnetic property. Here, we covalently linked Fe(Salen) to paclitaxel (PTX), a widely used anti-cancer drug, to obtain a magnetized paclitaxel conjugate (M-PTX), which exhibited magnetic characteristics for magnet-guided drug delivery and MRI visualization. M-PTX increased apoptosis and G2/M arrest of cultured human oral cancer cell lines in the same manner as PTX. Furthermore, marked contrast intensity was obtained in magnetic resonance imaging (MRI) of M-PTX. In a mouse oral cancer model, a permanent magnet placed on the body surface adjacent to the tumor resulted in distinct accumulation of M-PTX, and the anti-cancer effect was greater than that of M-PTX without the magnet. We believe that this strategy may improve future cancer chemotherapy by providing conventional anti-cancer drugs with novel functionalities such as magnet-guided drug delivery or MRI-based visualization/quantitation of drug distribution.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 24570

Publication Alerts

Research Papers:

Treatment of oral cancer using magnetized paclitaxel

Abstract